Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights key studies in acute coronary syndromes, emphasizing the importance of early diagnosis, evidence-based treatments, tailored antiplatelet therapy, and novel biomarkers for risk stratification.
Acute coronary syndromes or ACS are an emergency that should be diagnosed and managed as soon as possible. ST-segment elevation myocardial infarctions are an absolute emergency (‘time is muscle’),1 whereas non-ST-segment elevation myocardial infarctions should be revascularized within 48 h at the latest according to guidelines.2 While for the former, symptoms and the ECG are crucial, for the latter biomarkers have become the standard practice,3,4 although the recent rule-out algorithm has been controversially discussed, particulalry in intermediate risk patients.5 This aspect is addressed in a timely review article entitled ‘Early diagnosis of acute coronary syndrome’ by Hugo A. Katus and colleagues from the Heidelberg University in Germany.6 Indeed, the diagnostic evaluation of acute chest pain has been improved recently by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule out acute myocardial infarction earlier after initial presentation in the emergency department, which facilitates prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permits better utilization of healthcare resources. A non-trivial proportion of patients, however, fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The following specific ‘indeterminate’ patient categories have to be considered: (i) patients with symptoms and high-sensitivity cardiac troponin below the 99th percentile; (ii) patients with symptoms and high-sensitivity troponin below the 99th percentile, but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin above the 99th percentile, but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin above the 99th percentile and dynamic change, but without coronary plaque rupture, erosion, or dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is ‘indeterminate’, and these areas of uncertainty should be addressed in future research. The management of ACS is a true success story: at the time of Eisenhower’s seminal heart attack on 23 September 1955, mortality was staggeringly high, and Wall Street panicked after hearing the news. Neither ECG nor any biomarkers were available, nor had defibrillation been introduced and CPR was unknown to physicians. None of the currently used drugs had been developed, except morphine for pain relief. Today, mortality of ACS has dramatically decreased ∼6-fold thanks to modern medicine.7 In their manuscript entitled ‘Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation ofevidence-based treatments:experiences from the SWEDEHEART registry 1995–2014’, Karolina Szummer and colleagues from the Karolinska Institutet in Stockholm, Sweden analysed the impact of changes of treatments on outcomes in ST-elevation myocardial infarction, the condition that hit Eisenhower half a century ago, in their amazing real-life SWEDEHEART registry between 1995 and 2014.8 The authors remind us that most changes in treatment and outcomes occurred from 1994 to 2008. Importantly, evidence-based treatments increased: reperfusion from 66.2% to 81.7%, primary percutaneous coronary intervention from 4.5% to 78.0%, dual antiplatelet therapy from 0% to 89.6%, statin use from 14.1% to 93.6%, beta-blocker prescriptions from 78.2% to 91.0%, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers from 40.8% to 85.2%. As a consequence, 1-year mortality decreased from 22.1% to 14.1% and cardiovascular death from 20.1% to 11.1%, myocardial infarction from 11.5% to 5.8%, while the decrease in stroke and heart failure was somewhat less at from 2.9 to 2.1% and from 7.1 to 6.2%, respectively. Thus, the authors conclude that the gradual implementation of new and established evidence-based treatments in patients with ST-segment elevation myocardial infarction during the last 20 years is associated with markedly prolonged survival and considerably lower risk of recurrent ischaemic events, although a plateauing is seen since around 2008. This remarkable progress is put into perspective in an Editorial by myself and Dr Slayman Obeid.9 P2Y12 blockers such as clopidogrel and, more recently, prasugrel and ticagrelor have revolutionized the management of patients after stenting and/or ACS.10 The newer molecules have significant ischaemic benefit over clopidogrel after ACS; however, both are associated with an increase in bleeding.11,12 In a FAST TRACK entitled ‘Benefit of evolutive dual antiplatelet therapy after acute coronary syndrome:theTOPIC (Timing Of Platelet Inhibition after acute Coronary Syndrome) randomized study’, Thomas Cuisset and colleagues from the Hôpital de la Timone in Marseille, France evaluated the benefit of switching from aspirin plus a new P2Y12 blocker to aspirin plus clopidogrel in ACS patients 1 month after the index event in an open-label, monocentric, randomized trial with 645 patients.13 Patients with ACS requiring coronary intervention, on aspirin and a new P2Y12 blocker, and without adverse events at 1 month were assigned to switch to aspirin and clopidogrel (evolutive strategy) or continuation of their drug regimen (standard strategy). The primary outcome was a composite of cardiovascular death, urgent revascularization, stroke, and bleeding episodes as defined by the BARC classification being ≥2 at 6 months (Figure 1). The primary endpoint occurred in 9.0% in the evolutive group and in 17.6% in the standard group. Ischaemic endpoints did not differ, while BARC bleeding events of ≥2 occurred in 3.4% in the evolutive group and in 10.2% in the standard group. Thus, an evolutive antiplatelet strategy is superior to a standard strategy to prevent ischaemic and bleeding complications following an ACS. The clinical implications of these findings are put into perspective in an interesting Editorial by Frans Van de Werf of the Katholieke Universiteit Leuven in Belgium.14 Subgroup analyses of the primary composite endpoint. Data are shown as the number of primary endpoint events per total number of patients in that subgroup and the event rate. Event rates were based on Kaplan Meyer estimation in time-to-first-event analyses. Hazard ratio is for the primary composite endpoint of cardiovascular death, unplanned hospitalization leading to urgent coronary revascularization, stroke and Bleeding Academic Research Consortium bleeding ≥2 at 1 year. The P-value for interaction represents the likelihood of interaction between the variable and the treatment (from Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. See pages 3070–3078). While patients with ST-elevation myocardial infarction nearly always present with an occlusion of the culprit artery, this is typically not the case in non-ST-elevation myocardial infarction. However, a subset of patients with total occlusion present as non-ST segment elevation myocardial infarction without classic ST-elevation on the ECG. This may lead to delay in diagnosis and further management of such patients. In their study entitled ‘Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis’, Deepak L. Bhatt and colleagues from Harvard Medical School in Boston, Massachusetts performed a meta-analysis, yielding seven studies with 40 777 patients, to estimate the difference in outcomes between totally occluded and non-occluded culprit arteries in patients with non-ST-segment elevation myocardial infarction.15 A total of 25.5% patients had an occluded culprit artery with a predominant infero-lateral distribution involving the right coronary artery in 40% and the left circumflex artery in 33%. With a total occlusion of the culprit artery, there was an increased risk of both major adverse cardiac events (MACE) with a relative risk of 1.41 and all-cause mortality with a relative risk of 1.67 (Figure 2). Thus, better risk stratification is needed to identify such high-risk ACS patients to facilitate earlier revascularization and potentially to improve outcomes, a need that is further discussed in an Editorial by Philippe Gabriel Steg from INSERM U698 and Hôpital Bichat-Claude Bernard in Paris, France.16 Forest plot comparing major cardiac adverse events (medium- to long-term) in total occlusion of culprit artery in non-ST segment elevation myocardial infarction patients (IV, inverse-variance; TO, total occlusion; SE, standard error; CI, confidence interval) (from Khan AR, Golwala H, Tripathi A, Bin Abdulhak AA, Bavishi C, Riaz H, Mallipedi V, Pandey A, Bhatt DL. Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis. See pages 3082–3089). A telomere is a DNA region of protective repetitive TTAGGG nucleotide sequences at each end of a chromosome which declines with age from ∼11 kb at birth to ∼4 kb in the elderly.17,18 It therefore has been involved in the ageing process. Indeed, telomere length is shortened by oxidative DNA damage, reflecting biological ageing.19 As age determines the outcome of many cardiovascular diseases, Charalambos Antoniades and colleagues from the University of Oxford in the UK explored the value of blood and vascular telomere length as biomarkers of oxidative stress in humans and in acute myocardial infarction in their manuscriupt entitled ‘Predictive value of telomere length on outcome following acute myocardial infarction:evidencefor contrasting effects of vascular vs. blood oxidative stress’.20 In a prospective cohort of 290 patients surviving a recent acute myocardial infarction, blood telomere length measured on admission was a strong predictor of 1-year all-cause mortality with a hazard ratio of 3.21 and of cardiovascular mortality with a hazard ratio of 3.96. Furthermore, blood telomere length was quantified in 727 patients undergoing coronary artery bypass grafting, and superoxide was measured in peripheral blood mononuclear cells as well as in the saphenous vein and mammary artery segments of the vascular system. Patients were genotyped for functional genetic polymorphisms in P22phox (which activates NADPH-oxidases), and vascular smooth muscle cells selected by genotype were cultured from vascular tissue. Short blood telomere length was associated with high superoxide levels in mononuclear cells, but not in vessels, whereas vascular telomere length was related to superoxide levels in mammary artery and saphenous veins. Angiotensin II to stimulate NADPH-oxidases increased superoxide and reduced telomere length in vascular smooth muscle of carriers of the high-responsiveness P22phox alleles. Thus, blood telomere length predicts cardiovascular outcomes after acute myocardial infarction, independently of age, whereas vascular telomere length is a tissue-specific, rather than a global biomarker of vascular oxidative stress. The lack of a strong association between blood telomere length and vascular telomere length reveals the importance of systemic as compared with vascular factors in determining clinical outcomes after acute myocardial infarction. These novel findings are critically assessed in an Editorial by Amir Rezvan from Emory University School of Medicine in Atlanta, Georgia.21 The editors hope that this issue of the European Heart Journal will be of interest to its readers.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: